Verizon and 2 Stocks BREAKING 52-Week Highs

Santarus (NASDAQ:SNTS): The recruitment for Pharming’s Study 1310, the US trial for Ruconest, continues with 68 patients already recruited. Within the next few weeks, the study expects a full enrollment of 75 patient, but the recent discovery of an internal oversight may delay the unblinding of the top-line data by as much as three months until the completion of the statistical package the FDA requires. This is currently being investigated. The shares have traded in a 52-week range of $2.40 to $6.99.

Investing Insights: 15 KEY Takeaways from Appleā€™s Blockbuster Event>>

Theragenics Corp. (NYSE:TGX): Theragenics is beginning a modified Dutch Auction tender offer in which it will purchase as much as $10M of its common stock. The terms of the offer provide Theragenics stockholders the ability to tender some or all shares at a price ranging from $2.00 to $2.40 per share. The shares have traded in a 52-week range of $1.18 to $2.10.

Verizon Communications (NYSE:VZ): The company has introduced its new shared data plans, which also provide unlimited voice and text messaging. These plans are not cheap though. If a user wishes to share 2GB a month between a smartphone and a tablet, it would total $110 a month. The shares have traded in a 52-week range of $32.28 to $43.23.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.